William Ackman
Bill Ackman runs hedge fund Pershing Square Capital, which he started in 2003 following the dissolution of Gotham Partners.
Ackman is a value investor with an activist bent. Activist investors agitate management for changes. He owns large positions in Target (NYSE: TGT) and Borders (NYSE: BGP). He has also been involved in activist situations at Wendy's (NYSE: WEN) and McDonald's (NYSE: MCD).
Ackman proved his acumen as a short seller in 2007/2008 as short positions he held in MBIA (NYSE: MBI) and Ambac (NYSE: ABK) proved to be big winners due to the credit crunch.
In July 2008, Ackman said he was short the common stock of Fannie Mae (NYSE: FNM) and Freddie Mac (NYSE: FRE). Ackman also laid out a plan to reorganize the GSEs, which would wipe out the common shareholders.
View Older Stories View More Recent Stories
-
Herbalife (HLF) Gains Intra-Day Despite Ackman Presentation
-
Bill Ackman, Pearson, Schiller Among Valeant's (VRX) Senate Hearing Wtnesses
-
Valeant names Papa CEO after he resigns from Perrigo
-
Valeant in talks to hire Perrigo's Papa as CEO: source
-
U.S. activist investors finding fewer opportunities; compromise more common
-
Debt-laden Valeant faces tough choices in asset sales
-
Debt-laden Valeant faces tough choices in asset sales
-
Lone Pine's Cypress Fund down 8 percent in first quarter, hurt by Valeant
-
BettingonZero.com Created by Herbalife (HLF)
-
Does Ackman's Film on Herbalife (HLF) Have A Disclosure Problem?
-
Exclusive: Valeant calls in investment banks to weigh options - sources
-
Legg Mason's Miller Thinks Valeant (VRX) Stock Could Double, Has Been Buying Shares
-
'Betting on Zero' Doesn't Have Distributor Yet - Bloomberg (HLF)
-
S&P Downgrades Valeant Pharma (VRX) to 'B'; Notes Escalation in Near-Term Default Risk
-
Hedge funds' billion-dollar club loses members in 2015
-
Herbalife (HLF) on Watch Ahead of 'Betting on Zero' Premiere
-
Wall St. ends higher but indexes post weekly losses
-
Ackman Shoots Down Idea of Valeant (VRX) Unloading Bausch & Lomb
-
Valeant gets extra month to file annual report
-
Pershing Square NAV/Share Up Modestly in April; YTD Return Ticked Higher Last Week
-
Valeant Pharma (VRX) Ramps to Session Highs
-
Ackman says Valeant may find new CEO in weeks, not months
-
Pershing Square's Ackman Says Valeant (VRX) was Passive Holding Until Recent, Board Focused on CEO Search
-
Ackman to face investor grilling after record quarterly loss
-
Ackman's fund falls 7 percent in March, hurt by Valeant
-
Regulator orders drugmaker Valeant management to cease trading
-
Historic 10-Year Anniversary of a Celebration of Heroes, Heart and Hope Gala in New York City Commemorating ‘A Decade of Difference’
-
Ackman's Amends Valeant Pharma (VRX) 13D to Add Director Consent for MCTO
-
Valeant CEO subpoenaed to testify before U.S. Senate panel
-
Senate's request for info from Ackman related to Valeant: source
-
Fitch: Pershing Square Holdings' 'BBB+' Ratings Not Yet Impacted by Valeant Decline
-
Ackman Doesn't See 'Slap on the Wrist' for Herbalife (HLF)
-
Ackman Sees Confidence Restored in Valeant Pharma (VRX) After 10-K Filed, New Leadership Identified
-
Ackman's hedge fund cooperating with U.S. on drug pricing probe: letter
-
Ackman Skipping Sohn Investment Conference to Focus on Valeant (VRX)
-
The Howard Hughes Corporation® Issues Letter to Shareholders
-
Valeant Pharma (VRX) Gains as Ackman Gets Hands On
-
Valeant (VRX) is Not Investable - Piper Jaffray
-
Valean (VRX) Changes Seen as Steps in the Right Direction - BMO Capital
-
Mizuho Sees More Volatility for Valeant (VRX) Amid Changes
-
Drugmaker Valeant CEO leaving as investor Ackman joins board
-
Valeant Pharma (VRX) to Replace CEO Pearson; Adds Bill Ackman to Board
-
Valeant Announces CEO Succession Plan And Changes To Board Of Directors; Provides Accounting And Financial Reporting Update
-
Wall St. ends flat as recent rally spurs caution
-
Activist hedge funds wounded by market turmoil
-
S&P says it may cut Ackman hedge fund's rating
-
Herbalife (HLF) Creeps Higher on Anti-Ackman Trade
-
Bill Ackman tells CNBC Valeant (VRX) "is a problem but we know what to do."
-
Bill Ackman tells CNBC next redemption Mid-May
-
Bill Ackman tells CNBC 'we don't use margin leverage - never have and never will' (VRX)

